10.1056/NEJMoa2301972 Jastreboff AM, Kaplan LM, Frías JP et al (2023) Triple-hormone-receptor agonist retatrutide for obesity—A Phase 2 Trial. Here, NR4A1 is linked to obesity due to melanocortin 4 receptor deficiency.